In the landmark FLOW clinical trial published in the New England Journal of Medicine, Semaglutide (Ozempic) reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease
If youd like help evaluating your GLP-1 exposure or designing a cost containment strategy ahead of your 2026 renewal, One World Cover would be happy to support
Our results are consistent with a post hoc analysis of the EXCEL trial [29] which concluded that exenatide combined with SGLT-2i reduced the risk of MACE (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) compared with exenatide monotherapy and also improved eGFR significantly
Packaging Each product is supplied in a laboratory-grade sealed glass vial , designed to protect the solution from contamination and environmental exposure during storage and transportation
I will keep everything in fridge in the future even thought the leaflet they send says otherwise, no wonder we all get confused
